Pulmatrix Q2 loss narrows on clinical development hold
Pulmatrix Q1 net loss narrows, clinical development on hold
Brief: Pulmatrix Announces Closing Of Preferred Stock Transaction As Part Of Planned Merger
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:59 AM
Brief: Pulmatrix Announces Termination Of Prior Planned Merger And Continues Pursuit Of Alternative Merger Opportunities
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:30 AM
Brief: Pulmatrix And Cullgen Continue To Pursue Merger
Biopharma Pulmatrix's Q3 revenue drops to $0 as trial ends, plans asset divestment
Brief: Pulmatrix Q3 EPS USD -0.24
Pulmatrix Q2 revenue falls to zero, net loss widens
Brief: Pulmatrix Announces Cross License Agreement And Transfer Of Laboratory To Mannkind Corporation
Brief: Pulmatrix Files For Mixed Shelf Of $95 Mln
Brief: Pulmatrix Inc, On March 7, Approved Termination Of Chief Medical Officer
Brief: Pulmatrix Announces FDA Acceptance Of Ind Application For Pur3100 To Treat Acute Migraine
Pulmatrix Inc reports results for the quarter ended in June - Earnings Summary
Pulmatrix Inc expected to post a loss of $1.23 a share - Earnings Preview
Brief: Pulmatrix Announces Submission Of IND Application To FDA
Brief: Pulmatrix Announces First Quarter 2023 Financial Results And Provides Corporate Update